Liver News and Research

RSS

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

12 Aug 2015

New Johns Hopkins study shows hepatitis C infection may spell heart trouble

People infected with the hepatitis C virus are at risk for liver damage, but the results of a new Johns Hopkins study now show the infection may also spell heart trouble.

12 Aug 2015

Breath analysis shows potential biomarkers for early-stage diagnosis of liver disease

A natural compound called limonene, which is found in oranges and lemons, could be indicative in early-stage diagnosis of liver disease, according to research published in the journal EBioMedicine by researchers in the Molecular Physics Group at the University of Birmingham.

12 Aug 2015

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.

11 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.

7 Aug 2015

BIDMC scientists discover new vitamin B3 pathway that regulates liver metabolism

Researchers at Beth Israel Deaconess Medical Center have identified a new vitamin B3 pathway that regulates liver metabolism. The discovery provides an opportunity to pursue the development of novel drug therapies to address obesity, type 2 diabetes and related metabolic diseases.

7 Aug 2015

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

An urban emergency department that set up a hepatitis C testing protocol saw high rates of infection among intravenous drug users and Baby Boomers, with three-quarters of those testing positive unaware they were infected.

7 Aug 2015

Newcastle University awarded £5M for drug development research

Cancer Research UK's Drug Discovery Committee has today (Friday) awarded Newcastle University's Northern Institute of Cancer Research £5M to bring more cancer drugs to clinical trials.

7 Aug 2015

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion Corporation, an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC).

6 Aug 2015

Vtesse reports preliminary results from VTS-270 Phase 1 trial for treatment of Niemann-Pick Disease Type C

Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.

6 Aug 2015

HHMI scientists identify stem cells that give rise to functional liver cells

Howard Hughes Medical Institute scientists have identified stem cells in the liver that give rise to functional liver cells. The work solves a long-standing mystery about the origin of new cells in the liver, which must constantly be replenished as cells die off, even in a healthy organ.

6 Aug 2015

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

In a collaborative study between Sanford Burnham Prebys Medical Discovery Institute and the Argonne National Laboratory, scientists have used a highly specialized X-ray crystallography technique to solve the protein structure of hypoxia-inducible factors (HIFs), important regulators of a tumor's response to low oxygen (hyopoxia).

6 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.

5 Aug 2015

Researchers find CD163 protein limits muscle repair after ischemic injury

Researchers have identified a protein produced by white blood cells that puts the brakes on muscle repair after injury. By removing the protein CD163 from mice, scientists at Emory University School of Medicine could boost muscle repair and recovery of blood flow after ischemic injury (damage caused by restriction of blood flow).

5 Aug 2015

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

5 Aug 2015

Liver News and Research

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

New Johns Hopkins study shows hepatitis C infection may spell heart trouble

Breath analysis shows potential biomarkers for early-stage diagnosis of liver disease

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

BIDMC scientists discover new vitamin B3 pathway that regulates liver metabolism

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

Newcastle University awarded £5M for drug development research

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Vtesse reports preliminary results from VTS-270 Phase 1 trial for treatment of Niemann-Pick Disease Type C

HHMI scientists identify stem cells that give rise to functional liver cells

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

Delcath Systems achieves record quarterly product revenue in Q2 2015

Researchers find CD163 protein limits muscle repair after ischemic injury

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Study finds evidence that gut microbes affect circadian rhythms, metabolism in mice

IP10 levels linked to HBsAg decline during TDF treatment

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

NYSCF scientists design new robotic platform to automate generation of patient-specific stem cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News